The vision to change the world
Life–changing therapy by global leaders in ophthalmology
Eyerising International is an Australian MedTech company developing life-impacting eye-health therapy to slow the progression of myopia. We are led by a team of world-renowned ophthalmology academics, researchers and a board with a proven track record in MedTech innovation, implementation, and clinical facilitation.
Patented childhood myopia control therapy
Eyerising International’s Myopia Management Repeated Low-Level Red–Light (RLRL) therapy was conceived and developed by ERI’s Chief Medical Officer, Professor Mingguang He, a global leader in myopia control and the development of artificial intelligence systems in ophthalmology. This innovation in childhood myopia control meets the quality, safety, and efficacy standards required by medical regulators in over 30 countries across Europe and Australasia.
View our most important scientific papers
Press releases
Tokyo Medical and Dental University Introduces the Eyerising Myopia Management Device for Their Myopia Patients
Melbourne, Australia - [July 9th, 2024] – Eyerising International is proud to announce that Tokyo Medical and Dental University will introduce the Eyerising Myopia Management Device for their myopia patients as part of their treatment[...]
Eyerising International is in Malaysia
We are proud partner with Transmedic to bring the Red Light #myopia management device to benefit Malaysian children suffering from myopia. Presenting at the WCPOS, a lot interests from clinicians. https://www.youtube.com/watch?v=GfFQqfbv-JM
A Game-Changer in Myopia Management is Now Available in Malaysia
We are excited to announce that our new partner in Malaysia, Transmedic Ophthalmology, will be launching and showcasing the Eyerising Myopia Management Device at the World Congress of Paediatric Ophthalmology and Strabismus (WCPOS) in Kuala[...]
Study Finds Red Light Therapy Cuts Ocular Elongation Rate and SER Increase
Article outlines the amazing results of RLRL in high myopia patients. “Repeated low-level red light demonstrates much stronger treatment efficacy among high myopia in children and adolescents aged six to 16 years, with 53.3% experiencing[...]
Professor Mingguang He
Founder, Chief Medical Officer
Prof. He has over 25 years of experience in ophthalmology. He is currently a Professor of Ophthalmic Epidemiology at the University of Melbourne and leads ophthalmic epidemiology research at the Centre for Eye Research Australia. His research has led to original articles and invited editorials in respected medical journals, including the Journal of the American Medical Association, Diabetes Care, & Ophthalmology.
Jason Sun
Founder, MD
With a clinical background and over 20+ years of executive experience in the Australian health sector, including 10 years of industry development experience, Mr. Sun brings expertise in Medtech commercialisation, international business, regulatory compliance, and government relations.
Michael Woods
Executive Director
Mr. Woods has been an investor, adviser, board member, and CEO for various life science start-ups and scale-up companies in the life sciences sector.
Manny Pascual
Head of Commercial
Over 20 years of experience in the medical device industry Previous Marketing Director for CooperVision Asia Pacific Previous success in medical device company business expansion and acceleration.
David Holland
Business Development Manager (Australasia)
Federico Roma
CTO Accomplished technology leader
Dr. Yuri Aung
Clinical Affairs and RAQA Manager
Dr. Lisa Zhuoting Zhu
Director of Clinical Development
For any investor questions, please send your queries to:
Email: info@eyerisinginternational.com
Eyerising International Pty Ltd
Head office
Suite 2.05
9/11 Claremont St
South Yarra VIC 3141
